ONC

Rating neutralTentativeAI Memo

BeOne Medicines

As of 2026-07-30/Confidence medium

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-07-30 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Report quality notice

memo remains a monitoring view with limited forward evidence and should not be standard-conviction

Action

neutral

Confidence

medium

Horizon

—

Key catalyst

Q2 2026 results on August 5 • 2026-08-05

Base target: $315 / p=45% prob

Biggest risk

The deterministic prior is negative across 5-, 20-, 60-, and 120-day horizons. Q2 expectations and post-print analyst revisions are unavailable, while regulatory execution, pipeline conversion, and recent insider selling create downside sensitivity.

Invalidation

Break below $275 or thesis failure.

What would change my mind?

Q1 2026 total revenue rose 35% to $1.5 billion, BRUKINSA revenue rose 38% to $1.1 billion, and adjusted diluted EPS was $3.24. [#SEC-8K-2026-05-06] Positive MANGROVE data and planned regulatory submissions could extend BRUKINSA's growth runway. Company IR source: https://ir.beonemedicines.com/news/beone-medicines-announces-positive-phase-3-results-for-brukinsa-in-frontline-mantle-cell-lymphoma/44597eac-a44b-451f-a021-48d345cdb85e

Research note

Recommendation

neutral

Confidence

medium

As of

2026-07-30

Base target

$315

p=45%

Bull target

$420

p=25%

Bear target

$275

p=30%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Recent insider-selling overhang
MANGROVE Phase 3 regulatory follow-through
Solid-tumor pipeline advancement

BearKey bullets

Early-stage solid-tumor data may not translate into pivotal-trial success or commercial revenue.
MANGROVE regulatory timing and approval or label outcomes remain uncertain.
Peer comparisons are broad rather than direct oncology or BTK comps.

WatchKey bullets

Q2 2026 results on August 5

Summary

High-level snapshot

Recommendation

neutral

Model confidence

medium

Timeframe

Asset

Equity

Trigger

Base case: $315 (p=45%)

Target spread vs base: +33% / -13%

Scenario probabilities

Bull Target: $420 (p=25%)Base Target: $315 (p=45%)Bear Target: $275 (p=30%)

Commentary

News flow is positive and dense around Q1 growth, ASCO/EHA data, and the MANGROVE readout, but social and analyst-revision coverage is unavailable. The deterministic model remains directionally negative, supporting a monitoring stance rather than a high-conviction bullish call.

As of 2026-07-30 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

Recent insider-selling overhang
MANGROVE Phase 3 regulatory follow-through
Solid-tumor pipeline advancement

Scenarios

Bull Target (Scenario probability)

$420 / p=25% prob

Base Target (Scenario probability)

$315 / p=45% prob

Bear Target (Scenario probability)

$275 / p=30% prob

Analysis 2026-07-30 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

Sentiment unavailable: insufficient coverage

Events

Other notable items detected

EVENT2026-08-05
Q2 2026 results on August 5
BeOne scheduled its second-quarter 2026 results and management webcast for August 5, 2026. The packet does not provide consensus or guidance expectations, so the directional surprise is unknown. [#PR-EARNINGS-2026-07-17]
Prob 100.00% • Move 4.00% • Priced-in 65.00%

Short-term Catalysts

Next few weeks

Recent insider-selling overhang
2026-10-28
Recent Form 4 filings show open-market sales by the CEO and SVP/general counsel. This is a sentiment signal only and is not evidence about operating performance. [#SEC-FORM4-2026-07-22] [#SEC-FORM4-2026-07-24]
Prob 60% • Move -3% • Priced-in 40%

Long-term Catalysts

Months to a year

MANGROVE Phase 3 regulatory follow-through
2027-07-30
The company reported positive frontline mantle-cell-lymphoma Phase 3 results for BRUKINSA plus rituximab, including a 43% reduction in progression or death versus bendamustine plus rituximab, and planned global regulatory submissions in the second half of 2026. Timing and label outcome remain uncertain. Company IR source: https://ir.beonemedicines.com/news/beone-medicines-announces-positive-phase-3-results-for-brukinsa-in-frontline-mantle-cell-lymphoma/44597eac-a44b-451f-a021-48d345cdb85e
Prob 55% • Move 8% • Priced-in 45%
Solid-tumor pipeline advancement
2027-07-30
Company-reported ASCO data covered BGB-43395, BG-C9074, and BGB-B2033, with several programs moving toward pivotal development during 2026. These remain clinical-development opportunities rather than established revenue drivers. Company IR source: https://ir.beonemedicines.com/news/beone-medicines-highlights-accelerating-solid-tumor-pipeline-with-new-data-at-asco-2026/c65de266-8b5a-4002-9ce8-e13b2564f924
Prob 45% • Move 10% • Priced-in 30%

Risks

Early-stage solid-tumor data may not translate into pivotal-trial success or commercial revenue.
MANGROVE regulatory timing and approval or label outcomes remain uncertain.
Peer comparisons are broad rather than direct oncology or BTK comps.
Q2 revenue, earnings, guidance, and consensus-surprise data are not available in the packet.
Recent CEO and officer open-market sales may weigh on sentiment.

Peers

Symbol	Summary
ALNY	Same-sector, similar-market-cap reference, but a loose comparison because its commercial and therapeutic mix differs from BeOne's oncology focus.
REGN	Established same-sector biopharma reference with larger scale; useful for commercial-biopharma context but not a clean BTK/oncology peer.
AMGN	Large curated same-sector reference with materially greater scale; broad valuation context only.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-07-30

Loading AI feed…

Symbol

Summary

ALNY

Same-sector, similar-market-cap reference, but a loose comparison because its commercial and therapeutic mix differs from BeOne's oncology focus.

REGN

Established same-sector biopharma reference with larger scale; useful for commercial-biopharma context but not a clean BTK/oncology peer.

AMGN

Large curated same-sector reference with materially greater scale; broad valuation context only.